Evaluation of therapeutic vaccine in patients with advanced lung cancer treated in Primary Health Care

Abstract

A study to evaluate the safety and effectiveness of CIMAvax EGF therapeutic vaccine in patients with lung cancer non-small cell stage IIIB or IV treated in primary health care in the province is done during the year Guantánamo, 2011. It was important the insertion of patients with cytohistological confirmation of non-small cell carcinoma of lung in advanced stages who were not candidates for oncospecific therapies because lesions were progressing after receiving supportive care or palliative. 35 patients were evaluated, only 11 of these completed the inclusion and exclusion criteria. Adverse events were registered such as: fever, injection site pain and vomiting. The death rate in the study was 54. 5 %. The survival time was 3. 1 month and survival at inclusion, 1.8 months. The quality of life the patients improved significantly, with low dyspnea and incorporation of patients to their families.